Sg3 Management, LLC Iovance Biotherapeutics, Inc. Call Options Transaction History

Sg3 Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $464,212 - $826,000	82,600 New	82,600 $527,000
Q1 2022 May 16, 2022	SELL	$12.38 - $19.1 $1.42 Million - $2.2 Million	-115,000 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$16.55 - $27.63 $595,800 - $994,680	-36,000 Reduced 23.84%	115,000 $2.2 Million
Q3 2021 Nov 15, 2021	BUY	$20.35 - $26.63 $1.44 Million - $1.89 Million	71,000 Added 88.75%	151,000 $3.72 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $489,899 - $992,100	30,000 Added 60.0%	80,000 $2.08 Million
Q1 2021 May 17, 2021	SELL	$28.67 - $52.59 $2.15 Million - $3.94 Million	-75,000 Reduced 60.0%	50,000 $1.58 Million
Q3 2020 Nov 13, 2020	BUY	$27.75 - $36.3 $1.33 Million - $1.75 Million	48,100 Added 62.55%	125,000 $4.12 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $1.96 Million - $2.95 Million	71,900 Added 1438.0%	76,900 $2.11 Million
Q1 2020 May 12, 2020	BUY	$19.54 - $38.85 $97,700 - $194,250	5,000 New	5,000 $150,000

313

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.